Boehringer Ingelheim International Gmbh

Boehringer Ingelheim Pharmaceuticals, Inc.

Aerie Pharmaceuticals, Inc.

Boehringer Ingelheim Pharma Gmbh & Co Kg

John David Ginn

Michael Robert Turner

Weimin Liu

Zhonghua Zhang

Ronald John Sorcek

Sabine K Schlyer

Frank Wu

Todd Bosanac

Christopher Ronald Sarko

Erick Richard Roush Young

Daniel Richard Marshall

Anthony S Prokopowicz

Michael Dennis Lowe

Jehrod Burnett Brenneman

Erick Richard Young

Eugene R Hickey

Denice Mary Spero

Sanxing Sun

Tina Marie Morwick

Robert Sibley

Roger John Snow

Thomas Martin Kirrane, Jr

Charles Lawrence Cywin

Peter Allen Nemoto

Can Mao

Maolin Yu

Darren DiSalvo

John A Westbrook

Di Wu

Edward S Tasber

Cheng-Kon Shih

Eugene Richard Hickey

Tamara Denise Hopkins

Pier Francesco Cirillo

Ming-Hong Hao

Mario G Cardozo

Derek Cogan

Angela Kay Berry

Yunlong Zhang

Zhidong Chen

Jiang-Ping Wu

Fariba Soleymanzadeh

Roman Wolfgang Fleck

Jonathan Emillian Emeigh

Anthony S Prokopowicz, Iii

George Dahmann

Thomas Martin Kirrane

Sabine Schyler

Disclosed are novel substituted 2H-isoquinolin-1-one and 3H-quinazolin-4-one derivatives useful as inhibitors of Rho kinase and for treating a variety of diseases and disorders that are mediated or sustained through the activity of Rho kinase, including cardiovascular diseases, pharmaceutical compositions comprising such compounds, methods for using such compounds and processes for making such compounds.

Rho kinase inhibitors

The present invention relates to compounds of formula (I): and pharmaceutically acceptable salts thereof, wherein R, R, R, R, R, Rand Rare as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.

Alkoxy pyrazoles as soluble guanylate cyclase activators

The present invention relates to compounds of formula I: and pharmaceutically acceptable salts thereof, wherein R, R, R, R, R, R, R, R, B, V, W, X, Y, Z and m are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.

Heterocyclic carboxylic acids as activators of soluble guanylate cyclase

The present invention relates to compounds of formula (I): and pharmaceutically acceptable salts thereof, wherein Rand X are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.

The present invention relates to compounds of formula (I): and pharmaceutically acceptable salts thereof, wherein Rto R, A, B, X, and n are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.

CXCR3 receptor antagonists

The present invention relates to compounds of formula (I): and pharmaceutically acceptable salts thereof, wherein R-Rand n are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.

Soluble guanylate cyclase activators

Isoquinolinone Rho kinase inhibitors

The present invention relates to compounds of formula (I): and pharmaceutically acceptable salts thereof, wherein Rto R, A, B, X, Y and n are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.

Disclosed are compounds of formula (I): wherein Rand Rare defined herein, which are useful as inhibitors of the kinase activity of the I&#x3ba;B kinase (IKK) complex. The compounds are therefore useful in the treatment of IKK mediated diseases including autoimmune diseases inflammatory diseases, cardiovascular disease and cancer. Also disclosed are pharmaceutical compositions comprising these compounds and processes for preparing these compounds.

[object Object]

Disclosed are novel compounds of formula (I): wherein R, Rand Rare as defined herein, which are useful as inhibitors of PKC-theta and are thus useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of PKC-theta, including immunological disorders and type II diabetes. This invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.

Pyrimidine derivatives useful as inhibitors of PKC-theta

Disclosed are compounds of the formula I shown below, wherein R1, R2, R3 and R4 are described herein, which are active as anti-inflammatory agents. Also disclosed are methods of using and making such compounds 

Substitute benzothiophene compounds

Disclosed are compounds of formula (I):wherein Rand Rare defined herein, which are useful as inhibitors of the kinase activity of the I&#x3ba;B kinase (IKK) complex. The compounds are therefore useful in the treatment of IKK mediated diseases including autoimmune diseases inflammatory diseases and cancer. Also disclosed are pharmaceutical compositions comprising these compounds and processes for preparing these compounds.

Substituted 3-amino-thieno [2,3-b]pyridine-2-carboxylic acid amide compounds and processes for preparing and their uses

Growing community of inventors

New Milford, CT, United States of America

John David Ginn